GlassScriptPhysician profile
Stacy J Tanner
NPI 1598020935
$5,243.09
in general payments reported to CMS, 2019-2025
23 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $550 · 2021: $325 · 2022: $18.02 · 2023: $702 · 2024: $1,896 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,250 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,249.61 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,446.27 | 2020-2025 | Rinvoq |
| Amgen INC. | $974.90 | 2020-2025 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $519.60 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $405.44 | 2023-2025 | Saphnelo |
| Pfizer INC. | $353.96 | 2020-2025 | |
| Janssen Biotech, INC. | $283.07 | 2020-2025 | Tremfya, Stelara |
| Aurinia Pharma U.S., INC. | $200.98 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $128.42 | 2020-2025 | Benlysta |
| Kiniksa Pharmaceuticals International, Plc | $124.24 | 2024 | Arcalyst |
| Lilly USA, LLC | $117.35 | 2020-2024 | Taltz |
| Sobi, INC | $92.77 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $77.57 | 2023-2025 | Strensiq, Ultomiris |
| Mallinckrodt Hospital Products INC. | $77.44 | 2024-2025 | Acthar |
| Sandoz INC. | $74.08 | 2024-2025 | Hyrimoz |
| Organon LLC | $60.56 | 2024-2025 | Hadlima, Renflexis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.08 | 2020-2024 | Ofev |
| Fresenius Kabi USA, LLC | $50.17 | 2024-2025 | Stimufend |
| Kyowa Kirin, INC. | $48.98 | 2023 | Crysvita |
| Ucb, INC. | $45.69 | 2023-2025 | Bimzelx, Cimzia |
| Genentech USA, INC. | $33.56 | 2025 | Gazyva |
| E.R. Squibb & Sons, L.L.C. | $28.16 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $23.29 | 2020 | |
| Radius Health, INC. | $21.51 | 2025 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.